Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Camrelizumab + Rivoceranib in Mixed HCC-CCA
NCT07105748Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in combined hepatocellular cholangiocarcinoma (cHCC-iCCA), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Started Aug 2025; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
combined hepatocellular cholangiocarcinoma (cHCC-iCCA)
Beyond the preview
Go deeper on NCT07105748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105748.